Series of three patients with periocular squamous cell carcinoma treated with HeberFERON®. Case report
Abstract
Introduction: periocular squamous cell carcinoma is a malignant tumor of the keratinizing cells of the epidermis and its annexes. Therapeutics focuses on its elimination without functional and aesthetic sequelae. HeberFERON® –currently in phase IV clinical trial– is a drug that, due to its synergistic antiproliferative effect, is a valid option to treat this tumor.
Objective: to present a series of three patients diagnosed with periocular squamous cell carcinoma in whom the treatment was effective.
Case presentation: three patients were treated with HeberFERON®. The first two presented squamous cell carcinomas on the periocular surface: one conjunctival-corneal and one tarsoconjunctival; in both, the medicine was used by the intramuscular and intralesional routes. The third patient had a cutaneous squamous cell carcinoma of the upper eyelid, treated with intralesional injection. In the first two the tumors were considerably reduced, but total resolution was achieved with minimally invasive surgical interventions. In the third, the tumor was also reduced and with the use of cryotherapy the operation was avoided.
Conclusions: treatment with HeberFERON® of periocular squamous cell carcinomas was effective in all three patientsDownloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The journal is not responsible for the opinions and concepts expressed in the works, which are the exclusive responsibility of the authors. The Editor, with the assistance of the Editorial Committee, reserves the right to suggest or request advisable or necessary modifications. Original scientific works are accepted for publication, as are the results of research of interest that have not been published or sent to another journal for the same purpose.
The mention of trademarks of specific equipment, instruments or materials is for identification purposes, and there is no promotional commitment in relation to them, neither by the authors nor by the editor.
